Objectives: Stratified mucin-producing intraepithelial lesion (SMILE) is an uncommon premalignant lesion of the uterine cervix. A detailed examination of preinvasive SMILE cases including a comparison of the cytologic features with usual-type adenocarcinoma in situ (AIS) and human papillomavirus (HPV) genotyping was performed. Study Design: Excisions and preceding Papanicolaou (Pap) tests were retrieved from the files of 2 tertiary care centers. Histologic review estimated the lesional SMILE proportion. Pap tests were reviewed and assessed for architectural, cellular and background features. Cobas® HPV test was performed. Results: 13 cases were identified. Mean/median patient age was 35/33 years (range 23-51 years). Concurrent high-grade squamous intraepithelial lesion was found in 10/13 (77%) and AIS in 8/13 (62%) cases. In 6 cases, SMILE was dominant (≥50%) and represented in 5/6 corresponding Pap tests. Cytology interpretations differed more often in the SMILE-dominant group (p < 0.05). SMILE and AIS had overlapping features. Feathering and prominent nucleoli were absent in SMILE. HPV DNA was detected in all 12 cases tested. HPV 18 was most common (7/12). Excisions with positive/suspicious margins were reported in 5/6 SMILE-dominant versus 3/7 nondominant cases. Conclusion: SMILE is best considered as an AIS variant for cytologic, etiologic and management purposes. Cytologic features overlap with AIS, but are more subtle and easily missed. HPV testing may play a role in facilitating SMILE detection.

1.
Park JJ, Sun D, Quade BJ, Flynn C, Sheets EE, Yang A, et al: Stratified mucin-producing intraepithelial lesions of the cervix: adenosquamous or columnar cell neoplasia? Am J Surg Pathol 2000;24:1414-1419.
2.
Wilbur DC, Colgan TJ, Ferenczy AS, Hirschowitz L, Loening T, McCluggage WG, et al: Glandular tumours and precursors; in Kurman RJ, Carcangiu ML, Herrington CS, Young RH (eds): WHO Classification of Tumours of Female Reproductive Organs, ed 4. Lyon, IARC, 2014, pp 183-206.
3.
Gupta S, Parsons P, Saha A, Wight C: Follow-up of patients with SMILE (stratified mucin-producing intraepithelial lesion) on the cervix - a dilemma. Eur J Obstet Gynecol Reprod Biol 2010;148:207-209.
4.
Boyle DP, McCluggage WG: Stratified mucin-producing intraepithelial lesion (SMILE): report of a case series with associated pathological findings. Histopathology 2015;66:658-663.
5.
Backhouse A, Stewart CJ, Koay MH, Hunter A, Tran H, Farrell L, et al: Cytologic findings in stratified mucin-producing intraepithelial lesion of the cervix: a report of 34 cases. Diagn Cytopathol 2016;44:20-25.
6.
Lastra RR, Park KJ, Schoolmeester JK: Invasive stratified mucin-producing carcinoma and stratified mucin-producing intraepithelial lesion (SMILE): 15 cases presenting a spectrum of cervical neoplasia with description of a distinctive variant of invasive adenocarcinoma. Am J Surg Pathol 2016;40:262-269.
7.
Goyal A, Yang B: Cytologic features of stratified mucin-producing intraepithelial lesion of the cervix - a case report. Diagn Cytopathol 2014;42:792-797.
8.
Schwock J, Rouzbahman M, Geddie WR: Stratified mucin-producing intraepithelial lesion of the cervix: a diagnostic challenge. Cytojournal 2014;11:22.
9.
Hipp J, Ali SZ: Stratified mucin-producing intraepithelial lesions of the cervix: a diagnostic challenge in cytopathology. Mod Pathol 2016;96(suppl 2):102A.
10.
Henry MR, Russell DK, Luff RD, Prey MU, Wright TC Jr, Nayar R: Epithelial cell abnormalities: squamous; in Nayar R, Wilbur DC (eds): The Bethesda System for Reporting Cervical Cytology, ed 3. Heidelberg, Springer, 2015, pp 135-192.
11.
Wilbur DC, Chhieng DC, Guidos B, Mody DR: Chapter 6: Epithelial cell abnormalities: glandular; in Nayar R, Wilbur DC (eds): The Bethesda System for Reporting Cervical Cytology, ed 3. Heidelberg, Springer, 2015, pp 193-240.
12.
Wilbur DC: Practical issues related to uterine pathology: in situ and invasive cervical glandular lesions and their benign mimics: emphasis on cytology-histology correlation and interpretive pitfalls. Mod Pathol 2016;29 (suppl 1):S1-S11.
13.
Clifford G, Franceschi S: Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix. Int J Cancer 2008;122:1684-1685.
14.
Sano T, Nakamura C, Yoshida T, Oyama T: Stratified mucin-producing intraepithelial lesions (SMILEs) of the uterine cervix are associated with HPV integration. Pathol Int 2014;64:628-630.
15.
Cha YJ, Koh MJ, Kim YT, Cho NH: Stratified mucin-producing intraepithelial lesion. Basic Appl Pathol 2012;5:72-75.
16.
Adegoke O, Kulasingam S, Virnig B: Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health 2012;21:1031-1037.
17.
Smith HO, Tiffany MF, Qualls CR, Key CR: The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States - a 24-year population-based study. Gynecol Oncol 2000;78:97-105.
18.
Bulk S, Visser O, Rozendaal L, Verheijen RH, Meijer CJ: Cervical cancer in the Netherlands 1989-1998: decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer 2005;113:1005-1009.
19.
Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al: Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011;12:663-672.
20.
Barroilhet L, Van Hanegem L, Bernstein M, Feldman S: Potential effects of updated Pap test screening guidelines and adenocarcinoma in situ of the cervix. Obstet Gynecol 2013;121:759-764.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.